BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/25/2025 4:18:44 PM | Browse: 12 | Download: 35
 |
Received |
|
2024-12-20 08:27 |
|
Peer-Review Started |
|
2024-12-20 08:27 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-01-10 05:40 |
|
Revised |
|
2025-01-12 10:13 |
|
Second Decision |
|
2025-02-06 02:35 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-02-07 02:22 |
|
Articles in Press |
|
2025-02-07 02:22 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-03-07 08:02 |
|
Publish the Manuscript Online |
|
2025-03-25 16:18 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Combining immune checkpoint inhibitors with standard treatment regimens in advanced human epidermal growth factor receptor-2 positive gastric cancer patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Sheng-Hu Zhang, Wan Li, Xi-Yan Chen and Le-Le Nie |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Le-Le Nie, Chief Physician, Department of General Surgery, The First People’s Hospital of Fuzhou City, No. 1099 Yingbin Avenue, Fuzhou 344000, Jiangxi Province, China. nielele520@163.com |
| Key Words |
Advanced; Human epidermal growth factor receptor 2-positive; Gastric cancer; Standard treatment regimen; Immune checkpoint inhibitors; Efficacy; Safety; Prognosis; Influencing factors |
| Core Tip |
Immune checkpoint inhibitors combined with standard treatment regimens for patients with advanced human epidermal growth factor receptor 2-positive gastric cancer demonstrate favorable clinical efficacy, significantly prolonging progression-free survival with manageable safety. Eastern cooperative oncology group performance status, peritoneal metastasis, positive programmed death-ligand 1 expression, and treatment regimen are independent factors influencing progression-free survival, warranting increased clinical attention to patients exhibiting these factors. |
| Publish Date |
2025-03-25 16:18 |
| Citation |
<p>Zhang SH, Li W, Chen XY, Nie LL. Combining immune checkpoint inhibitors with standard treatment regimens in advanced human epidermal growth factor receptor-2 positive gastric cancer patients. <i>World J Gastrointest Oncol</i> 2025; 17(4): 103855</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i4/103855.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i4.103855 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
